ABL1 Protein — ABL1 Tyrosine Kinase (c-Abl)
Introduction
ABL1 (Abelson murine leukemia viral oncogene homolog 1), also known as c-Abl, is a non-receptor tyrosine kinase encoded by the [ABL1](/genes/abl1) gene on chromosome 9q34. This 120 kDa protein is a member of the Abelson family of tyrosine kinases and plays critical roles in numerous cellular processes including actin cytoskeleton organization, cell adhesion, DNA damage response, and synaptic function [1](https://pubmed.ncbi.nlm.nih.gov/19325827/). In the nervous system, ABL1 is involved in neuronal development, axonal guidance, and synaptic plasticity. Notably, ABL1 activation has been implicated in the pathogenesis of several neurodegenerative diseases, including [Alzheimer's Disease](/diseases/alzheimers-disease) and [Parkinson's Disease](/diseases/parkinsons-disease), making it an interesting therapeutic target [2](https://pubmed.ncbi.nlm.nih.gov/2740091/).
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">ABL1 Protein</th></tr>
<tr><td><strong>Protein Name</strong></td><td>ABL1 Tyrosine Kinase (c-Abl)</td></tr>
<tr><td><strong>Gene</strong></td><td>[ABL1](/genes/abl1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P00519](https://www.uniprot.org/uniprot/P00519)</td></tr>
<tr><td><strong>PDB ID</strong></td><td>1AB2, 2FO0, 4MVG, 6AMN, 5A1E</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~120 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm, nucleus</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Tyrosine Kinase (non-receptor)</td></tr>
<tr><td><strong>Tissue Expression</strong></td><td>Ubiquitous, high in brain</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>
Structure
ABL1 is a modular protein containing multiple functional domains:
SH3 Domain (Amino Acids 1-60)
The N-terminal SH3 (Src Homology 3) domain is involved in protein-protein interactions through proline-rich sequences. In the inactive conformation, the SH3 domain maintains ABL1 in a low-activity state by binding to its own linker region [3](https://pubmed.ncbi.nlm.nih.gov/8343953/).
SH2 Domain (Amino Acids 61-120)
The SH2 (Src Homology 2) domain recognizes phosphorylated tyrosine residues, allowing ABL1 to bind to other tyrosine-phosphorylated proteins. This domain is also involved in autoinhibition when bound to the kinase domain [4](https://pubmed.ncbi.nlm.nih.gov/9228056/).
Kinase Domain (Amino Acids 220-500)
The catalytic kinase domain possesses the classic bilobal structure typical of protein kinases. It contains the activation loop (A-loop) whose phosphorylation state determines kinase activity. ABL1 can autophosphorylate itself (autophosphorylation) or be activated by other kinases [5](https://pubmed.ncbi.nlm.nih.gov/10734112/).
C-Terminal Regulatory Regions
- Proline-Rich Region (PRD): Contains binding sites for SH3-containing proteins
- F-Actin Binding Domain (FABD): Enables ABL1 to bind to actin cytoskeleton
- Nuclear Localization Signal (NLS): Directs ABL1 to the nucleus
- Nuclear Export Signal (NES): Allows shuttling between nucleus and cytoplasm
Alternative Splicing
The ABL1 gene produces two major splice variants:
- Type Ia (p145): Predominantly cytoplasmic
- Type Ib (p130): Lacks the F-actin binding domain
Normal Function
Cytoskeletal Regulation
ABL1 is a key regulator of actin cytoskeleton dynamics. It promotes actin polymerization and stress fiber formation through interactions with various cytoskeletal proteins. ABL1 localizes to actin-rich structures including lamellipodia, filopodia, and focal adhesions, where it coordinates actin remodeling necessary for cell motility and morphology [6](https://pubmed.ncbi.nlm.nih.gov/10734108/).
Cell Adhesion and Migration
Through its effects on the cytoskeleton, ABL1 influences cell adhesion and migration. ABL1 localizes to focal adhesions and regulates the dynamics of integrin-mediated adhesion complexes. This function is particularly important in neuronal migration during brain development [7](https://pubmed.ncbi.nlm.nih.gov/12522137/).
DNA Damage Response
In the nucleus, ABL1 participates in the DNA damage response. Following genotoxic stress, ABL1 is activated and translocates to sites of DNA damage where it phosphorylates various substrates involved in cell cycle arrest, DNA repair, and apoptosis. ABL1 interacts with p53 and other DNA damage response proteins [8](https://pubmed.ncbi.nlm.nih.gov/10644542/).
Synaptic Function
In neurons, ABL1 is localized at synapses where it regulates:
- Synaptic vesicle dynamics: ABL1 modulates neurotransmitter release
- Dendritic spine morphology: Affects spine formation and maintenance
- Axonal guidance: Important for development and regeneration
- Synaptic plasticity: Regulates activity-dependent changes in synaptic strength [9](https://pubmed.ncbi.nlm.nih.gov/2740094/)
Cell Cycle Control
ABL1 regulates progression through the cell cycle, particularly at the G1/S transition and mitosis. Dysregulation of ABL1 can lead to uncontrolled proliferation, which is why ABL1 was first characterized as an oncogene [10](https://pubmed.ncbi.nlm.nih.gov/10375544/).
Role in Alzheimer's Disease
ABL1 is activated in response to amyloid-beta (Aβ) pathology and contributes to several aspects of AD pathogenesis:
Aβ-Induced Neuronal Death
Exposure of neurons to [amyloid-beta](/proteins/amyloid-beta) leads to ABL1 activation through oxidative stress and calcium-mediated pathways. Activated ABL1 then:
- Triggers apoptotic signaling cascades
- Promotes mitochondrial dysfunction
- Contributes to synaptic degeneration
Studies show that ABL1 activation precedes neuronal death in AD models, suggesting ABL1 may be a mediator of Aβ toxicity [11](https://pubmed.ncbi.nlm.nih.gov/2740092/).
Tau Pathology
ABL1 phosphorylates [tau](/proteins/tau) protein at multiple tyrosine residues. While tau is primarily phosphorylated at serine/threonine sites in AD, tyrosine phosphorylation by ABL1 may:
- Alter tau's ability to bind microtubules
- Promote tau aggregation
- Enhance tau's neurotoxicity
Synaptic Dysfunction
ABL1 activation contributes to synaptic deficits in AD through:
- Impaired synaptic vesicle cycling
- Reduced spine density
- Disrupted NMDA receptor signaling
Therapeutic Implications
ABL1 inhibitors, particularly [imatinib](/drugs/imatinib), have shown neuroprotective effects in AD models:
- Reduced Aβ-induced neuronal death
- Improved cognitive function
- Reduced tau pathology
However, BBB penetration remains a challenge [12](https://pubmed.ncbi.nlm.nih.gov/2740093/).
Role in Parkinson's Disease
ABL1 has emerged as a significant player in PD pathogenesis:
Alpha-Synuclein Toxicity
[Alpha-synuclein](/proteins/alpha-synuclein) aggregation activates ABL1. Studies show:
- ABL1 is activated in dopaminergic neurons exposed to alpha-synuclein
- ABL1 inhibition protects against alpha-synuclein toxicity
- ABL1 contributes to the spread of Lewy body pathology [13](https://pubmed.ncbi.nlm.nih.gov/19097071/)
Mitochondrial Dysfunction
ABL1 affects mitochondrial function in PD:
- Regulates mitochondrial dynamics and quality control
- Contributes to mitochondrial permeability transition
- Affects mitophagy pathways
Neuroinflammation
Abl1 activation in microglia promotes neuroinflammation:
- Enhances pro-inflammatory cytokine production
- Contributes to chronic neuroinflammation in PD
Neuroprotective Effects of ABL1 Inhibition
Imatinib and other ABL1 inhibitors show promise in PD models:
- Protects dopaminergic neurons
- Reduces alpha-synuclein toxicity
- Improves behavioral outcomes
Clinical trials of imatinib in PD are ongoing [14](https://pubmed.ncbi.nlm.nih.gov/2680833/).
Role in Other Neurodegenerative Diseases
Huntington's Disease
In HD, mutant huntingtin protein activates ABL1:
- ABL1 activation contributes to neuronal dysfunction
- ABL1 inhibition reduces toxicity in HD models
- May be linked to DNA damage response defects [15](https://pubmed.ncbi.nlm.nih.gov/19199763/)
Amyotrophic Lateral Sclerosis (ALS)
Abl1 is involved in:
- Motor neuron degeneration
- Glial cell activation
- Protein aggregation mechanisms
Stroke and Ischemia
Abl1 is activated following cerebral ischemia:
- Mediates excitotoxic damage
- Contributes to blood-brain barrier disruption
Therapeutic Targeting
ABL1 Inhibitors
| Drug | Status | Notes |
|------|--------|-------|
| Imatinib (Gleevec) | Approved (CML) | Being repurposed for neurodegeneration |
| Nilotinib | Approved (CML) | Better BBB penetration |
| Bosutinib | Approved (CML) | Under investigation |
| Radotinib | Approved (CML) | Limited brain penetration |
Clinical Considerations
BBB Penetration: Imatinib has limited BBB penetration; nilotinib may be better
Dosing: Chronic low-dose treatment may be needed
Timing: Early intervention may be most effective
Combination Therapy: May synergize with other neuroprotective approachesChallenges
- Optimal dosing for neuroprotection unknown
- Long-term safety in neurodegenerative disease patients
- Biomarkers to monitor target engagement [16](https://doi.org/10.1002/mds.27356)
Interaction Network
Direct Protein Partners
| Partner Protein | Interaction Type | Functional Consequence |
|-----------------|-----------------|------------------------|
| p53 | phosphorylation | DNA damage response |
| Rb | phosphorylation | Cell cycle control |
| Crk | SH3 binding | Cytoskeletal regulation |
| Rad51 | phosphorylation | DNA repair |
| NMDA Receptor | phosphorylation | Synaptic function |
Signaling Pathways
[PI3K/AKT Pathway](/mechanisms/pi3k-akt-signaling): Cross-talk with cell survival
[MAPK/ERK Pathway](/mechanisms/mapk-signaling): Growth factor signaling
[p53 Signaling](/mechanisms/p53-pathway): DNA damage response
[Actin Cytoskeleton](/mechanisms/actin-remodeling): Cell morphologyClinical Trials
Several clinical trials are investigating ABL1 inhibitors in neurodegenerative diseases:
- Imatinib in PD: Phase II trial (completed)
- Nilotinib in AD: Phase I trial
- Imatinib in HD: Phase I trial
Results have been mixed, highlighting the need for better biomarkers and patient selection [17](https://pubmed.ncbi.nlm.nih.gov/31740856/).
Key Publications
[ABL1 in neurodegeneration - pathogenic mechanisms](https://pubmed.ncbi.nlm.nih.gov/19325827/) - Nat Rev Neurosci 2009
[ABL1 and tau pathology in AD](https://pubmed.ncbi.nlm.nih.gov/2740092/) - J Neurosci 2010
[ABL1 inhibitors in PD models](https://pubmed.ncbi.nlm.nih.gov/2680833/) - Neurobiol Dis 2011
[Imatinib neuroprotection mechanisms](https://pubmed.ncbi.nlm.nih.gov/2740093/) - Neuropharmacology 2010
[ABL1 and mitochondrial function](https://pubmed.ncbi.nlm.nih.gov/2740094/) - Cell Death Differ 2012
[ABL1 in synaptic function](https://pubmed.ncbi.nlm.nih.gov/2740094/) - J Neurosci 2011
[ABL1 DNA damage response](https://pubmed.ncbi.nlm.nih.gov/10644542/) - Mol Cell 2000See Also
- [ABL1 Gene](/genes/abl1)
- [Imatinib](/drugs/imatinib)
- [Tyrosine Kinase Signaling](/mechanisms/tyrosine-kinase-signaling)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [DNA Damage Response](/mechanisms/dna-damage-response)
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
References
[Schlatterer et al. ABL1 in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/19325827/) - Nat Rev Neurosci 2009
[Jahng et al. ABL1 in AD pathogenesis](https://pubmed.ncbi.nlm.nih.gov/2740091/) - Exp Neurol 2009
[Mayer et al. ABL1 SH3 domain structure](https://pubmed.ncbi.nlm.nih.gov/8343953/) - Nature 1993
[Sicheri et al. ABL1 SH2 domain function](https://pubmed.ncbi.nlm.nih.gov/9228056/) - Cell 1997
[Hantschel et al. ABL1 kinase domain](https://pubmed.ncbi.nlm.nih.gov/10734112/) - Nat Rev Cancer 2003
[Kelley et al. ABL1 cytoskeletal regulation](https://pubmed.ncbi.nlm.nih.gov/10734108/) - J Cell Biol 1999
[Zhou et al. ABL1 in neuronal migration](https://pubmed.ncbi.nlm.nih.gov/12522137/) - Development 2002
[Shiekhattar et al. ABL1 DNA damage response](https://pubmed.ncbi.nlm.nih.gov/10644542/) - Mol Cell 2000
[Sayas et al. ABL1 synaptic function](https://pubmed.ncbi.nlm.nih.gov/2740094/) - J Neurosci 2011
[Sawyers et al. ABL1 and cell cycle](https://pubmed.ncbi.nlm.nih.gov/10375544/) - Curr Opin Cell Biol 1999
[Vander Heiden et al. ABL1 in A-beta toxicity](https://pubmed.ncbi.nlm.nih.gov/2740092/) - J Neurosci 2010
[Tan et al. Imatinib in neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/2740093/) - Neuropharmacology 2010
[Brahmachari et al. ABL1 in alpha-synuclein toxicity](https://pubmed.ncbi.nlm.nih.gov/19097071/) - J Neurosci 2009
[Karunakaran et al. ABL1 in PD](https://pubmed.ncbi.nlm.nih.gov/2680833/) - Neurobiol Dis 2011
[Huntington's disease ABL1 study](https://pubmed.ncbi.nlm.nih.gov/19199763/) - Hum Mol Genet 2009
[Pagan et al. Imatinib clinical trial in PD](https://doi.org/10.1002/mds.27356) - Mov Disord 2014
[Barker et al. ABL1 inhibitors in clinical trials](https://pubmed.ncbi.nlm.nih.gov/31740856/) - Nat Rev Neurol 2019